Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10496MR)

This product GTTS-WQ10496MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10496MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14913MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ69MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ5458MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ12757MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ10110MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ999MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ15712MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ15130MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SYD985
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW